Constipation Treatment Market Size and Share
Market Overview
| Study Period | 2020 - 2031 |
|---|---|
| Market Size (2026) | USD 13.97 Billion |
| Market Size (2031) | USD 18.84 Billion |
| Growth Rate (2026 - 2031) | 6.17% CAGR |
| Fastest Growing Market | North America |
| Largest Market | Asia Pacific |
| Market Concentration | Medium |
Major Players *Disclaimer: Major Players sorted in no particular order Image © Mordor Intelligence. Reuse requires attribution under CC BY 4.0. | |
Constipation Treatment Market Analysis by Mordor Intelligence
The Constipation Treatment Market size is projected to expand from USD 13.22 billion in 2025 and USD 13.97 billion in 2026 to USD 18.84 billion by 2031, registering a CAGR of 6.17% between 2026 to 2031.
Prescription volumes for opioid analgesics remain high, locking many patients into chronic opioid-induced constipation regimens even as public-health campaigns attempt to reduce misuse. At the same time, e-commerce pharmacies shorten purchase paths and lift over-the-counter laxative penetration, especially among price-sensitive consumers. Secretagogues and other novel mechanisms win formulary access in irritable bowel syndrome with constipation, yet payers increasingly prefer lower-cost alternatives, nudging the product mix toward generic osmotics. Consolidation among branded manufacturers accelerates as patent cliffs loom, while digital biofeedback tools certified as software medical devices start to siphon volume from drug therapies.
Key Report Takeaways
- By drug class, stimulant agents led with 38.62% of the constipation treatment market share in 2025, whereas lubricant agents are forecast to expand at a 7.06% CAGR through 2031.
- By disease type, opioid-induced constipation captured 34.07% of the value in 2025, while the irritable bowel syndrome with constipation sub-segment is expected to accelerate at a 9.63% CAGR to 2031.
- By prescription type, prescription medicines accounted for 61.92% of revenue in 2025, yet over-the-counter formulations are projected to grow at an 8.08% CAGR during the same horizon.
- By route of administration, oral formulations accounted for 75.78% of sales in 2025, and the oral route is anticipated to grow at an 8.41% CAGR, outpacing rectal products.
- By patient type, adults represented 61.08% of treated patients in 2025, although the geriatric cohort is advancing at an 8.82% CAGR, the fastest among all groups.
- By distribution channel, hospital pharmacies held 34.78% of distribution revenue in 2025, while online and direct-to-consumer channels are expanding at a 7.83% CAGR as telehealth bundles drive subscription refills.
Note: Market size and forecast figures in this report are generated using Mordor Intelligence’s proprietary estimation framework, updated with the latest available data and insights as of 2026.
Global Constipation Treatment Market Trends and Insights
Drivers Impact Analysis*
| Driver | (~) % Impact on CAGR Forecast | Geographic Relevance | Impact Timeline |
|---|---|---|---|
| Aging Population Boosts Chronic-Use Demand | +1.2% | Global, strongest in North America, Europe, Japan | Long term (≥ 4 years) |
| Opioid Prescription Surge Driving OIC | +1.5% | North America, Europe | Medium term (2-4 years) |
| E-Commerce Accelerates OTC Laxative Uptake | +0.9% | Global, early gains in North America, Asia-Pacific cities | Short term (≤ 2 years) |
| Mid-Stage Gut-Targeted Neuromodulators | +0.7% | North America, Europe | Long term (≥ 4 years) |
| Microbiome & Digital Adherence Innovations | +0.6% | North America, Western Europe, Australia | Medium term (2-4 years) |
| Approvals of New GC-C and 5-HT4 Agonists | +1.3% | Global, regulatory leads in US, EU, Japan | Medium term (2-4 years) |
| Source: Mordor Intelligence | |||
Aging Population Boosts Chronic-Use Demand
People aged 65 and above numbered 761 million in 2025 and are projected to reach 994 million by 2030, a shift that raises baseline constipation prevalence to more than 26%.[1]United Nations DESA, “World Population Ageing 2025,” un.org Long-term care facilities mandate prophylactic osmotic or bulk-forming agents, turning these products into recurring, annuity-style prescriptions. Japan, where 29.1% of citizens are older than 65, reported a 14% rise in laxative scripts among those over 75 during 2025. Higher Parkinson’s and diabetes incidence further entrenches multi-year regimens. Manufacturers answer with low-sodium, palatable formulas aligned with the 2024 Beers Criteria update, which flags high-osmolarity products for deprescribing.
Opioid Prescription Surge Driving OIC Therapies
The United States dispensed 142.2 million opioid prescriptions in 2024, only 7% below 2023, sustaining a large cohort at risk for opioid-induced constipation.[2]Centers for Disease Control and Prevention, “U.S. Opioid Dispensing Rate Maps,” cdc.gov Up to 81% of chronic-opioid patients experience OIC, yet fewer than one-quarter receive a peripherally acting mu-opioid receptor antagonist, leaving an undertreated pool that often presents in emergency care for fecal impaction. European regulators widened methylnaltrexone labeling in 2024, enlarging the non-cancer pain segment. Physicians increasingly redirect to GC-C agonists like linaclotide off-label to bypass prior-authorization barriers, spurring interest in fixed-dose opioid–laxative combinations that minimize therapeutic gaps.
E-Commerce Accelerates OTC Laxative Penetration
Online sales of OTC laxatives in the United States jumped 34% year over year in 2025, compared with 4.2% in physical retail.[3]National Association of Chain Drug Stores, “2025 Pharmacy Market Trends Report,” nacds.org Direct-to-consumer subscription kits lower per-unit costs by 22% and deliver discreet packaging that reduces stigma, drawing first-time buyers who had avoided in-store purchases. Amazon Pharmacy’s algorithmic storefront funnels same-day delivery across 12 cities, pressuring competitors to match convenience or shed share. Regulatory oversight lags: the FDA issued 17 warning letters in 2025 for unapproved stimulant combinations. Yet private-label brands now command 29% of online category revenue, squeezing premium manufacturers’ pricing latitude.
Pipeline Gut-Targeted Neuromodulators Enter Mid-Stage Trials
Several Phase II neuromodulators showed 53% symptom relief versus 29% for placebo, earning FDA Breakthrough Therapy designation in 2025. These agents aim to normalize enteric nervous signaling without conventional pro-secretory effects, potentially redefining moderate-to-severe treatment algorithms. Venture funding gravitates toward start-ups that pair such molecules with digital adherence coaching to maximize real-world persistence. If successful, these entrants could compress demand for stimulant and osmotic agents that dominate current chronic protocols.
Restraints Impact Analysis*
| Restraint | (~) % Impact on CAGR Forecast | Geographic Relevance | Impact Timeline |
|---|---|---|---|
| Adverse-Effect & Dependency Fears | -0.8% | Global, strongest in North America and Europe | Medium term (2-4 years) |
| Stricter OTC Stimulant / Sodium-Phosphate Rules | -0.6% | North America, Europe, Australia | Short term (≤ 2 years) |
| Biofeedback Platforms Cannibalize Drug Spend | -0.5% | North America, Western Europe | Medium term (2-4 years) |
| Consumer Shift to Herbal & Home Remedies | -0.4% | Global, notable in Asia-Pacific and Latin America | Long term (≥ 4 years) |
| Source: Mordor Intelligence | |||
Adverse-Effect & Dependency Fears Curb Long-Term Use
A 2025 FDA surveillance review showed that 19% of chronic stimulant users developed hypokalemia serious enough to require hospitalization. Advocacy groups caution against more than 14 straight days of stimulant use, and cohort data reveal a 34% dose-escalation rate within 18 months, validating dependency concerns. Health Canada’s advisory linking high-dose polyethylene glycol to aspiration pneumonia in frail seniors has driven nursing homes toward fiber-based agents despite a slower onset.
Stricter OTC Stimulant / Sodium-Phosphate Regulations
The FDA shifted certain sodium phosphate laxatives to prescription-only status in 2024, erasing USD 87 million in annual OTC revenue. Australia capped bisacodyl pack sizes in early 2025, while the European Commission’s labeling harmonization proposal forces manufacturers to add dependency warnings well before the 2027 deadline. Compliance costs thin the field, granting scale players extra shelf space but limiting consumer choice.
*Our forecasts treat driver/restraint impacts as directional, not additive. The impact forecasts reflect baseline growth, mix effects, and variable interactions.
Segment Analysis
By Drug Class: Secretagogues Reshape Prescription Mix
Stimulant agents accounted for 38.62% of segment revenue in 2025, reflecting their low cost and rapid onset, yet lubricant formulas are projected to grow at a 7.06% CAGR as microencapsulation reduces aspiration risk among elders. Osmotic agents remain first-line in hospital protocols, though their 5.8% growth lags the 6.17% baseline of the constipation treatment market. Secretagogues already command premium pricing, and their patents expiring in 2027-2028 could invite biosimilars that compress margins.
Bulk-forming products enjoy a reputation for “natural” relief but require high fluid intake that deters frail patients. Stool softeners, chiefly docusate, slide after a Cochrane review showed no clear efficacy, leading the American College of Gastroenterology to downgrade them in 2025 guidance. Peripherally acting mu-opioid receptor antagonists occupy a specialized OIC niche but endure payer hurdles that limit uptake compared with off-label GC-C alternatives.
By Disease Type: IBS-C Outpaces Chronic Idiopathic Constipation
Opioid-induced constipation retained 34.07% of disease-type value in 2025, yet IBS-C is forecast to sprint ahead at a 9.63% CAGR, the fastest among all indications. Chronic idiopathic constipation remains the largest absolute pool but grows more slowly as patients experiment with diet, fiber supplements, and app-based biofeedback.
Rome IV criteria revisions in 2024 effectively expanded the IBS-C population by lowering the symptom-frequency threshold, enlarging the patient pool for GC-C and 5-HT4 agonists. Prucalopride prescriptions surged 27% in 2025 after pediatric European approval stimulated brand visibility. Neurologic constipation continues to be underserved, reflecting split care pathways between neurology and gastroenterology practices.
By Prescription Type: OTC Gains Traction Despite Regulation
Prescription drugs accounted for 61.92% of sales in 2025, but the OTC category is predicted to grow at an 8.08% CAGR as copayment burdens and prior-authorization delays frustrate patients. The anticipated 2028 generic entry for linaclotide could blur prescription-OTC boundaries, with manufacturers weighing lower-dose OTC switches.
Stronger enforcement against high-risk stimulant combinations modestly curbs OTC growth, yet e-commerce continues to expand its reach: 41% of Amazon Pharmacy laxative buyers in 2025 were first-time purchasers. Private-label products thrive online, capturing a larger slice of category spend than in physical outlets.
By Route of Administration: Oral Dominance Continues
Oral products represented 75.78% of 2025 revenue and are poised to expand at an 8.41% CAGR, faster than the overall constipation treatment market. Taste-masked powders, chewables, and orally disintegrating tablets target swallowing issues and sensory decline in older adults, reinforcing the route’s popularity.
Rectal options occupy acute rescue scenarios, and parenteral products such as subcutaneous methylnaltrexone remain confined to palliative care due to USD 37–42 per-dose costs. The constipation treatment market share for suppositories is inching upward within long-term care as caregivers prioritize predictable evacuation timings.
By Patient Type: Geriatric Growth Outpaces Other Cohorts
Adults accounted for 61.08% of users in 2025, but geriatric patients posted an 8.82% CAGR, eclipsing that of every other group. Institutional protocols often require routine laxatives, creating durable volume streams.
Manufacturers reformulate products with reduced sodium and improved taste to suit cardiovascular comorbidities and sensory decline. Pediatric needs receive renewed attention following the FDA’s 2024 label expansion of polyethylene glycol for infants over six months.
By Distribution Channel: Online Pharmacies Disrupt Traditional Models
Hospital pharmacies controlled 34.78% of 2025 value because of bundled inpatient protocols, yet online and direct-to-consumer services are advancing at a 7.83% CAGR. Retail drugstores, while holding the largest absolute slice, face margin compression and rising private-label penetration.
Price studies show average online OTC prices running 18% below in-store equivalents, intensifying traffic migration. Regulatory warning letters introduce compliance risk, but uneven enforcement allows numerous platforms to operate in a gray zone.
Geography Analysis
North America captured 39.43% of 2025 revenue on the back of high per-capita health spending and entrenched opioid prescribing that feeds the OIC segment. Canada expanded linaclotide coverage in its two largest provinces during 2024, prompting a 23% rise in prescriptions. Mexico remains bifurcated: metropolitan centers mirror U.S. treatment patterns, while rural areas lean on herbal senna, leaving prescription penetration at 34% of diagnosed cases.
Germany, the United Kingdom, and France supply 62% of regional turnover, but single-payer cost controls push clinicians toward generics. Takeda’s newly approved 5-HT4 agent still awaits favorable price agreements in Italy and Spain, delaying uptake. NICE guidance updates that emphasize fiber and lifestyle adjustment dampen prescription volume in the United Kingdom.
Asia-Pacific posts the fastest regional CAGR at 11.27%. China’s decision to add linaclotide to provincial reimbursement lists in 2024, India’s low-priced generic GC-C launches, and Japan’s super-aged demographic collectively propel growth. Australia’s stimulant pack-size caps inadvertently shift chronic users to prescription items, while South Korea leverages telemedicine to broaden specialist access.
Middle East and Africa together represent a modest 7% share but record steady expansion as Gulf states upgrade health infrastructure. South America grows at 6.9%; Brazil’s approval of plecanatide in 2024 and local generic launches keep prices accessible. Economic volatility in Argentina continues to push consumers toward locally made stimulants.
Regulatory Landscape
Regulation in constipation therapies centers on safety oversight for chronic OTC use and indication expansion for established prescription brands. In the United States, the FDA tightened oversight of OTC stimulant combinations and pursued product-level actions that reshape access and channel strategies. In 2026 regulators expanded access through label and geographic approvals. The FDA's May 2026 approval of LINZESS (linaclotide) for pediatric functional constipation down to age 2 and the NMPA's May 2026 approval of naldemedine tosylate (Symproic) for adult opioid-induced constipation in China after regional pathway progress in the Guangdong-Hong-Macao Greater Bay Area illustrate the global shift.
Competitive Landscape
The constipation treatment market remains fragmented. Mergers and divestitures intensify as patents expire: Grünenthal bought Movantik for USD 250 million in 2024, and Ipsen exited the category by selling Forlax for EUR 350 million in 2025. Multinationals focus on lifecycle management, extending exclusivity through pediatric labels and orally disintegrating formulations, whereas generic players rush bioequivalence filings to seize post-patent share.
Digital therapeutics emerge as non-drug competitors. FDA-cleared biofeedback apps reduce rescue-drug use, prompting incumbents to explore hybrid bundles; Ironwood piloted an adherence-coaching partnership for Linzess in 4 U.S. states in 2025. Patent data show AbbVie and Takeda staking claims in neuromodulators and microbiome modulators, signaling a pivot toward novel pathways with lower risk of electrolyte imbalance.
Smaller biotechs face steep commercialization hurdles. Ardelyx achieved only 12% U.S. formulary coverage for tenapanor by mid-2025, while Evoke Pharma’s asset changed hands for USD 28 million as part of a repositioning gamble. Private-label OTC growth online further erodes pricing power for traditional brands, hastening strategic portfolio pruning.
Constipation Treatment Industry Leaders
Takeda Pharmaceutical Company Ltd
Ironwood Pharmaceuticals, Inc.
AstraZeneca Plc
Sanofi S.A.
Bausch Health Companies Inc. (Salix Pharmaceuticals)
- *Disclaimer: Major Players sorted in no particular order
Market Opportunities and Future Outlook
Whitespace in constipation care is most visible in pediatrics, refractory chronic constipation, and opioid-induced constipation pathways where adherence, tolerability, and payer access constrain durable outcomes. The May 2026 FDA expansion of LINZESS to pediatric functional constipation in children aged 2 years and older provides a concrete opening for companies with pediatric development and dosing strategies, and it raises competitive emphasis on age-appropriate formulations, safety monitoring, and payer positioning in pediatric GI. Emerging modalities such as device-led and digital adjunct approaches are gaining formal clinical traction as alternatives for hard-to-treat patients and as complements to drug regimens. Regional regulatory programs in the Guangdong-Hong-Kong-Macao Greater Bay Area and ongoing GI research signal a broader strategy to enter supportive-care constipation medicines and reduce reliance on rescue interventions.
Recent Industry Developments
- May 2026: The US FDA approved LINZESS (linaclotide) for functional constipation in pediatric patients 2 years of age and older, expanding the pediatric label and intensifying competition around pediatric dosing and coverage decisions.
- May 2026: The NMPA approved naldemedine tosylate (Symproic) for adult opioid-induced constipation in China, following earlier regional pathway progress in the Guangdong-Hong-Kong-Macao Greater Bay Area, signaling enhanced local entry for supportive-care constipation medicines.
- June 2024: Nestle Health Science acquired VOWST, an oral microbiota-based therapy, expanding its GI portfolio with a modality that sits adjacent to conventional constipation pharmacotherapy, signaling growing strategic interest in gut microbiome platforms across functional GI disorders.
Research Methodology Framework and Report Scope
Market Definition and Coverage
This market covers revenues generated from therapies used to manage and treat constipation across OTC and prescription settings, including drug classes and related treatment options used in routine clinical care. Values are captured at the level where products are sold into healthcare and consumer channels.
Scope exclusions: procedures and broader digestive wellness services are excluded unless they are directly part of constipation treatment spending.
Segmentation Overview
- By Drug Class
- Bulk-Forming Agents
- Osmotic Agents
- Stimulant Agents
- Stool Softeners / Emollients
- Lubricant Agents
- Secretagogues (ClC-2, GC-C)
- Other Drug Classes
- By Disease Type
- Chronic Idiopathic Constipation (CIC)
- Irritable Bowel Syndrome-C (IBS-C)
- Opioid-Induced Constipation (OIC)
- Post-surgical & Neurologic Constipation
- By Prescription Type
- Over-the-Counter (OTC)
- Prescription Drugs
- By Route of Administration
- Oral
- Rectal
- Parenteral
- By Patient Type
- Adult
- Geriatric
- Pediatric
- By Distribution Channel
- Hospital Pharmacies
- Retail / Drug Stores
- Online Pharmacies & DTC Subscriptions
- By Geography
- North America
- United States
- Canada
- Mexico
- Europe
- Germany
- United Kingdom
- France
- Italy
- Spain
- Rest of Europe
- Asia-Pacific
- China
- Japan
- India
- Australia
- South Korea
- Rest of Asia-Pacific
- Middle East & Africa
- GCC
- South Africa
- Rest of Middle East & Africa
- South America
- Brazil
- Argentina
- Rest of South America
- North America
Data Sources, Market Sizing, and Validation
Desk Research
Desk work starts by building the disease and treatment context so the model is anchored to real care patterns. We refer to public sources such as the US CDC, US FDA drug and safety updates, NIH and NLM resources, and the WHO, along with peer-reviewed gastroenterology journals and selected national health statistics portals.
To convert that context into sizing inputs, we also review company annual reports, earnings notes, investor decks, product labeling, and reputable press coverage that indicates launches, indications, and channel shifts. Where helpful, paid subscriptions for company financials and news intelligence, plus patent databases, are used to cross-check timelines and product activity. These sources are illustrative only, and many other public references were used to collect, validate, and clarify data points.
Primary Interviews and Surveys
Primary work is used to test what desk findings cannot fully confirm, mainly therapy mix, typical treatment duration, and how OTC and prescription choices shift by patient type and disease type. We speak with a mix of clinicians, pharmacists, distributors, and industry roles across APAC, EMEA, and the Americas so assumptions on pricing, access, and adoption do not lean on one geography alone.
Table inputs are based on what these respondent groups clarify during the fieldwork, particularly around how constipation is treated in practice and how that translates into channel-level demand.
Distribution of primary research fieldwork respondents
| Company type | Respondent position | Region |
|---|---|---|
| Top tier: 29% | CXOs: 15% | APAC: 41% |
| Mid tier: 53% | Functional/Unit leaders: 34% | EMEA: 36% |
| Smaller Players: 18% | Managers: 51% | Americas: 23% |
Market-Sizing & Forecasting
Sizing is built using a top-down approach where epidemiology and treated-population signals are translated into demand by therapy category, and then converted to value using typical dosing and price bands across channels. The totals are then checked with selective bottom-up approximations, such as sample brand and molecule revenue indications, pharmacy channel checks, and volume times average selling price snapshots, which are used to adjust outliers.
Key inputs vary by country and are kept practical, including constipation prevalence and diagnosis rates, share of patients treated versus self-managed, OTC versus prescription mix, therapy duration patterns, route of administration split, and price progression by channel (retail, hospital, and online). When historical data is thin for smaller countries, gaps are handled by using proxy indicators like comparable treatment rates and healthcare access, and then validated with expert feedback.
For forecasting, scenario analysis is used around a base case, and it is guided by expected changes in treated cohorts, OTC switching behavior, product uptake, and pricing pressure. Where time series are stable, simple regression checks are added so the growth path stays consistent with the drivers that interviewees identify as most sensitive.
Data Validation & Update Cycle
Validation is done by comparing model outputs against independent signals, like prescription volume direction, channel share shifts, and country-level healthcare and population trends that should move in the same direction as treatment demand. When a variance is spotted, we re-check units, currency conversions, and the implied patient counts before accepting the update.
A multi-step analyst review is followed so assumptions, formulas, and country rollups are tested for logic and consistency. The report is refreshed annually, and interim updates are made when material events occur, such as major label changes, launches, or pricing disruptions. Before delivery, the latest public disclosures are reviewed again so clients receive a current view rather than an outdated snapshot.
Mordor Intelligence's Constipation Treatment Market Size Compared Against Other Published Estimates
It is common to see different market values for constipation treatment because groups do not always count the same therapies, channels, or patient categories, even when they use similar labels. Differences also come from which year is treated as the base, how prices are normalized across countries, and how aggressively future uptake is assumed.
In this study, the key gap drivers usually relate to whether OTC spending is captured alongside prescription products, whether opioid-induced and post-surgical constipation are included as distinct demand pools, and whether online pharmacy sales are measured as a separate channel or blended into retail. The spread can also widen when currency conversion timing and price inflation are applied differently, and when older assumptions are not re-tested with fresh checks.
Benchmark comparison
| Source | Market Size | Gaps in Research Methodology |
|---|---|---|
| Mordor Intelligence | USD 13.22 B (2025) | |
| Global Consultancy A | USD 19.88 B (2024) | Uses a different base year and appears to apply a broader value capture across treatment categories, which can push totals up if adjacent GI care or higher price assumptions are blended into the model. |
| Industry Research Group B | USD 9.93 B (2023) | Anchors on an earlier base year and may reflect narrower channel capture or a more conservative treated-population build, which typically lowers the starting point before growth is applied. |
The table shows that year selection, scope around OTC and specific constipation types, and pricing normalization explain most of the difference. By tying value back to treated cohorts, therapy mix, and channel-level pricing checks that are re-validated in interviews, the estimate is kept more traceable to real use and spend patterns, which is how the model is set up at Mordor Intelligence.
Key Questions Answered in the Report
How fast is the constipation treatment market projected to grow to 2031?
It is expected to expand from USD 13.97 billion in 2026 to USD 18.84 billion by 2031 at a 6.17% CAGR.
Which therapy class currently leads revenue?
Stimulant agents held 38.62% of 2025 revenue, topping all other classes.
What drives the strong growth in Asia-Pacific?
Wider reimbursement in China, low-cost generics in India, and Japan’s aging society lift regional demand at an 11.27% CAGR.
Why are over-the-counter laxatives gaining share?
E-commerce pharmacies and subscription bundles lower prices and bypass prior-authorization barriers, pushing OTC volume ahead at an 8.08% CAGR.
Which patient group grows fastest?
Geriatric patients advance at 8.82% annually, fueled by polypharmacy and institutional laxative protocols.
Page last updated on:
